Get Ready for the 941 Third Quarter Deadline with New 2025-2026 Bundle for ezPaycheck
The 2025-2026 combo release gives SMBs and Accountants an affordable way to streamline e941 form filing for upcoming Oct. 31 Deadline REDMOND, Wash., Oct. 20, 2025... Read more.
Sandvik: Interim report third quarter 2025
STOCKHOLM, Oct. 20, 2025 /PRNewswire/ — Order intake SEK 30,769 million (28,796) Order intake, at fixed exchange rates, increased by 16% Revenues SEK 29,218... Read more.
Hisense MEA Marks Real Madrid Partnership with Exciting Retail Promotions and Regional Gaming Competition
DUBAI, UAE, Oct. 20, 2025 /PRNewswire/ — Hisense MEA is connecting with football followers and uniting them across the region through a series of store promotions... Read more.
WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
SHANGHAI, Oct. 20, 2025 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today... Read more.
PINTEC’s Subsidiary ZIITECH Recognized by Austrade Under EMDG Program
BEIJING, Oct. 20, 2025 /PRNewswire/ — Pintec Technology Holdings Limited (Nasdaq: PT) (“PINTEC” or the “Company”), a leading technology... Read more.
Loyalty Juggernaut Launches GRAVTY® Agentic AI Compass: The World’s First Autonomous Loyalty Intelligence Suite
Empowering enterprises to run loyalty like a performance engine—transforming insight into impact and speed into strategic advantage through accountable Agentic... Read more.
FDA Grants Orphan Drug Designation to Cellenkos’ CK0803 Tregs for Treatment of Amyotrophic Lateral Sclerosis
Orphan Drug Designation granted to CK0803 for Amyotrophic Lateral Sclerosis CK0803 is CNS Homing Tregs expressing CXCR3hi, CXCR7+, LFA1+ CK0803 is planned for... Read more.
BTL’s EMSCULPT NEO Used in Astronaut Training in Hungary for International Space Mission
PRAGUE, Oct. 20, 2025 /PRNewswire/ — BTL, a global leader in medical technologies, proudly announces that its flagship device, EMSCULPT NEO, played a key... Read more.
The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95%... Read more.
Sobi Q3 2025 report: Accelerated growth and portfolio momentum
STOCKHOLM, Oct. 20, 2025 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2025 Third Quarter 2025... Read more.